Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3-4/2001

01-10-2001

Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry

Authors: Astrid T. Stormorken, Wolfram Müller, Britta Lemkemeyer, Jaran Apold, Juul T. Wijnen, Riccardo Fodde, Gabriela Möslein, Pål Møller

Published in: Familial Cancer | Issue 3-4/2001

Login to get access
Metadata
Title
Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry
Authors
Astrid T. Stormorken
Wolfram Müller
Britta Lemkemeyer
Jaran Apold
Juul T. Wijnen
Riccardo Fodde
Gabriela Möslein
Pål Møller
Publication date
01-10-2001
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 3-4/2001
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1023/A:1021151227983

Other articles of this Issue 3-4/2001

Familial Cancer 3-4/2001 Go to the issue

Instructions for Authors

Instructions-for-authors

Subject Index

Keyword index, Volume 1

Summary List

Abstracts presented at the XVth Symposium of the NetherlandsFoundation for the Detection of Hereditary Tumours,1 February 2002, Utrecht, The Netherlands

OriginalPaper

Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys

Commentary

Comment on Elit et al.: Prophylactic oophorectomy in Ontario

Authors Index

Acknowledgements
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits